Ms. Pai Panandiker is a seasoned commercial and operating leader with more than 20 years of global biopharmaceutical experience, including extensive leadership in neuroscience commercialization and in ...

Long-acting injectables (LAIs) were designed to solve this problem by reducing the burden of daily pill-taking and ensuring more consistent drug exposure. Underutilization of LAIs in the U.S is common ...

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday. The results underscore the ...

The U.S. Food and Drug Administration has approved a new drug for schizophrenia with a new mechanism of action for the first time in over 70 years. The treatment offers hope to thousands of patients ...

The U.S. Food and Drug Administration (FDA) approved a novel antipsychotic schizophrenia drug late Thursday, marking the first new treatment in decades for the mental health condition that affects 1.8 ...

Each year, about 100,000 Americans experience psychosis, a serious condition that disrupts thoughts and perceptions so ...

A new drug has been approved for the treatment of schizophrenia in adults. On Thursday, the U.S. Food and Drug Administration (FDA) approved COBENFY (xanomeline and trospium chloride), an oral ...

Schizophrenia medication falls under two main categories: older, first-generation, or "typical" antipsychotics and newer drugs for schizophrenia known as second-generation or "atypical" antipsychotics ...

Read full article: Dollars & Sense: The United States of Debt Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the ...